Intensification of basal insulin therapy with Lixisenatide in patients with type 2 diabetes in a real-world setting: the BASAL-LIXI Study

Publication date: Available online 9 October 2018Source: Current Therapeutic ResearchAuthor(s): Diego Bellido, Pablo Abellán, José Manuel Ruiz Palomar, Rogelio Álvarez Sintes, Andreu Nubiola, Virginia Bellido, Gracia Romero, Basal Lixi Study investigatorsABSTRACTPurposeBasal insulin reduces fasting blood glucose (FBG), but postprandial blood glucose (PPG) may remain higher. Traditional strategies with rapid insulin intensification can cause hypoglycemic episodes and weight gain. Glucagon-like peptide-1 receptor agonists, such as the short-acting lixisenatide, are able to control postprandial excursions, without weight gain, and with a low risk of hypoglycemic events. Due to the limited data on the combination of lixisenatide with basal insulin (±oral antidiabetic drugs, OADs) in clinical practice, this study evaluated changes in parameters associated with glycemic control and anthropometric data after 24 weeks of this therapy intensification.MethodsThis was a multicentre, retrospective observational study of 129 patients with uncontrolled type 2 diabetes on basal insulin. Their treatment was intensified by the addition of Lixisenatide at least 24 weeks prior to being included in the study. Data were retrospectively collected to determine changes in glycated hemoglobin (HbA1c) levels, blood glucose levels, weight and body mass index (BMI). Adverse reactions and hypoglycemic events were also recorded.FindingsAfter 24 weeks of therapy intensification with lixisenatide, a sig...
Source: Current Therapeutic Research - Category: Drugs & Pharmacology Source Type: research